PCSK9 Forum
Click here to forward this email to a colleague
Facebook Twitter RSS YouTube linkedin
Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact
ESC Congress Rome 2016
PCSK9 inhibition, plaque burden and cardiovascular events: Answers beckon

Experts discussed key questions at the 5th Closed Meeting of the PCSK9 Forum Editorial Board, 26th August, 2016 in Rome, Italy.

IVUS studies inform about achieved LDL cholesterol levels and plaque burden: What’s next?
Professor Steve Nicholls (South Australian Health & Medical Research Institute, Australia) overviews the current status of intravascular ultrasound (IVUS) studies evaluating the effects of LDL lowering on plaque burden. Will adding a PCSK9 inhibitor on top of background statin therapy provide further benefit?

GLAGOV (GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound, NCT01813422), expected later this year will provide key insights.

Read the report and view the slides »
Professor Steve NichollsProfessor Steve Nicholls

PCSK9 inhibitors: Who and when to treat?

Professor Tony Wierzbicki (Guy's & St Thomas' Hospitals, London, UK) discusses considerations for the use of PCSK9 inhibitors from the UK policy maker perspective.

Read the report and view the slides »
Professor Steve NichollsProfessor Tony Wierzbicki

In an accompanying Editorial, Professor Wierzbicki discusses findings from a recent US health economic and cost consequence analysis. With the first results from FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk, NCT01764633) with evolocumab anticipated early in 2017, will more accurate health economic modelling make a difference?

Read the report »

Added to this, PCSK9 Forum Editor Professor Henry Ginsberg (Columbia University, New York, USA) discusses the issues around cost-effectiveness analyses for PCSK9 monoclonal antibodies in high risk patients.

View the video »
Professor Henry Ginsberg

New and updated edition of our popular therapeutic guide

A second edition of the free introductory guide: PCSK9 Inhibition - New Therapies in Cardiovascular Risk Reduction is now available on the Forum’s website. This very popular book has been updated with the latest information discussing the biology and therapeutic potential of PCSK9 inhibition.

Read online » Download now »

Forward to colleagues »
  New eBook
Click here to forward this email to a colleague
Questions & Answers
Why are new treatments needed?
Read the full answer and other questions on the PCSK9 Forum »
Like us on Facebook
For the latest updates, PCSK9 news and analysis.
Follow us on Twitter
Hot topics, news and conference reports.
YouTube Channel
For videos, interviews and webcasts from leading experts.
Educational Partners
and Supporters
Amgen Lilly The Medicines Company pFizer Sanofi
Copyright PCSK9 Forum 2016. Please click here to unsubscribe from future mailings.